Navigation Links
BioMS Medical to present at 2008 BIO International Convention
Date:6/12/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, June 12 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Business Forum at the 2008 BIO International Convention in San Diego, California.

WHEN: Friday June 20th at 10:15 am (PDT)

WHERE: San Diego Convention Center, San Diego

About the 2008 BIO International Convention

The 2008 BIO International Convention, hosted by the Biotechnology Industry Organization, will feature keynotes from industry and global leaders, more than 175 breakout sessions, business partnering meetings, and numerous networking events. The convention also includes more than 200,000 square feet of exhibitions showcasing the latest advancements in biotechnology alongside an array of potential partners, service providers, and state and international delegations. For more information visit http://www.bio2008.org/.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medical announces first quarter 2008 results
3. BioMs Medical to present at TIDES(R) Conference
4. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
5. BioMS Medical Provides Update On Pipeline Products
6. BioMS Medical announces conference call and web cast for Annual General Meeting
7. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
8. BioMS Medical to present at EQUITIES Conference
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medical to present at BioCentury Conference
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... 2014 The report "Chocolate, Cocoa Beans, ... Prices, Geography Trend and Forecast (2011 - 2016)," ... geography and studies the major market drivers, restraints, and ... and Asia. , The global chocolate market is expected ... in 2016 at an estimated CAGR of 2.7% from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... BASEL, Switzerland, Dec. 5 Roche (SWX:,ROG.VX; RO.S) announced ... (Nasdaq: VMSI ), as required by Ventana,s bylaws, ... of directors at,Ventana,s 2008 annual stockholders meeting., On ... acquire all of the,outstanding common shares of Ventana for ...
... Cost, Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur, Associated ... ... 11% Increase in Indicative Dividend for 2008 and Declares ... Quarterly Dividend, * Revises 2007 Full-Year GAAP EPS Guidance to ...
... January for lead antibody program ... ... Inc. (TSX:,ARI), a biotechnology company discovering and developing the next wave of,antibody ... transfer agreement for its CD44 Cancer,Stem Cell antibody with Avid Bioservices, a ...
Cached Biology Technology:Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 2Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 3Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 4Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 5Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 6Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 7Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 3Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 4Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 5Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 6Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 7Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 9Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 10Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 11ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 2ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... 16, 2013) A team of American and Chinese conservationists ... counted nearly 1,000 wild yaks from a remote area of ... this species, which was decimated by overhunting in the mid ... rugged area called Hoh Xil a national nature reserve ...
... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new journal, Journal ... ). JUOGR is to publish ... practices in the area of evaluation, development and management ...
... $14 million from the William & Nancy Thompson Family ... County, UC Irvine is helping lead the charge against ... in the U.S. autism., The funding created the ... which will provide unparalleled access to assessment, diagnosis, care ...
Cached Biology News:Yaks are back 2UCI research turns the corner on autism 2UCI research turns the corner on autism 3
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: